Recursion Pharmaceuticals, Inc. RXRX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s stock-based comp?
- Recursion Pharmaceuticals, Inc. (RXRX) reported stock-based comp of $22.22M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s stock-based comp decreased by 38.4% year-over-year, from $36.06M to $22.22M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s stock-based comp has grown at a 65.5% compound annual growth rate (CAGR), from $14.84M to $111.22M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.